Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell...

AL Amyloidosis Therapeutics Market is projected to rise at a 7.3% CAGR until 2033, being valued at US$ 4.56 billion | Future Market Insights, Inc. NEWARK, Del, March 20, 2023 (GLOBE NEWSWIRE) -- The global AL amyloidosis therapeutics market is expected to be worth US$ 2.25 billion by the year of 2023. The market, which is estimated to be worth...

TLX66 Meets Study Objectives in Patients with AL Amyloidosis MELBOURNE, Australia and SOUTHAMPTON, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s bone marrow...

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month BORDENTOWN, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today...

Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage IV, HR=0.413, p=0.025, over 9 months)SPA agreement...